Columbotai Bio-B announced that the new drug clinical trial application for SKB105, a targeted integrin beta-6 antibody conjugate drug independently developed by the company, has been approved by the Drug Evaluation Center of the China National Drug Administration.

Zhitongcaijing · 5d ago
Columbotai Bio-B announced that the new drug clinical trial application for SKB105, a targeted integrin beta-6 antibody conjugate drug independently developed by the company, has been approved by the Drug Evaluation Center of the China National Drug Administration.